Summit Therapeutics Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Summit Therapeutics Inc. (SMMT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $37.57 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-23
- Summit Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $37.57M, a 246.71% increase from fiscal 2024.
- Summit Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $10.84M, a 47.74% decline from fiscal 2023.
- Summit Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $20.73M, a 68.99% increase from fiscal 2022.
- Summit Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $12.27M, a 45.51% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $37.57M 10-K · filed 2026-02-23 |
| 2024-12-31 | $10.84M 10-K · filed 2026-02-23 |
| 2023-12-31 | $20.73M 10-K · filed 2026-02-23 |
| 2022-12-31 | $12.27M 10-K · filed 2025-02-24 |
| 2021-12-31 | $22.52M 10-K/A · filed 2022-12-21 |
| 2020-12-31 | $8.80M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |